{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:19:09Z","timestamp":1784204349159,"version":"3.55.0"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014013","name":"UKRI","doi-asserted-by":"crossref","award":["MC_PC_20029"],"award-info":[{"award-number":["MC_PC_20029"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100014013","name":"UKRI","doi-asserted-by":"crossref","award":["UKRI MC_PC 19075"],"award-info":[{"award-number":["UKRI MC_PC 19075"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"crossref"}]},{"name":"HDRUK","award":["MC_PC_19004"],"award-info":[{"award-number":["MC_PC_19004"]}]},{"name":"MRC","award":["MR\/V028367\/1"],"award-info":[{"award-number":["MR\/V028367\/1"]}]},{"name":"HDRUK","award":["HDR-9006"],"award-info":[{"award-number":["HDR-9006"]}]},{"DOI":"10.13039\/100014013","name":"UKRI","doi-asserted-by":"crossref","award":["ES\/S007393\/1"],"award-info":[{"award-number":["ES\/S007393\/1"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"crossref"}]},{"name":"MRC","award":["MC_UU_00022\/2"],"award-info":[{"award-number":["MC_UU_00022\/2"]}]},{"name":"CSO","award":["SPHSU17"],"award-info":[{"award-number":["SPHSU17"]}]},{"name":"NRS","award":["SCAF\/15\/02"],"award-info":[{"award-number":["SCAF\/15\/02"]}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Several countries restricted the administration of ChAdOx1 to older age groups in 2021 over safety concerns following case reports and observed versus expected analyses suggesting a possible association with cerebral venous sinus thrombosis (CVST). Large datasets are required to precisely estimate the association between Coronavirus Disease 2019 (COVID-19) vaccination and CVST due to the extreme rarity of this event. We aimed to accomplish this by combining national data from England, Scotland, and Wales.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods and findings<\/jats:title>\n<jats:p>We created data platforms consisting of linked primary care, secondary care, mortality, and virological testing data in each of England, Scotland, and Wales, with a combined cohort of 11,637,157 people and 6,808,293 person years of follow-up. The cohort start date was December 8, 2020, and the end date was June 30, 2021. The outcome measure we examined was incident CVST events recorded in either primary or secondary care records. We carried out a self-controlled case series (SCCS) analysis of this outcome following first dose vaccination with ChAdOx1 and BNT162b2. The observation period consisted of an initial 90-day reference period, followed by a 2-week prerisk period directly prior to vaccination, and a 4-week risk period following vaccination. Counts of CVST cases from each country were tallied, then expanded into a full dataset with 1 row for each individual and observation time period. There was a combined total of 201 incident CVST events in the cohorts (29.5 per million person years). There were 81 CVST events in the observation period among those who a received first dose of ChAdOx1 (approximately 16.34 per million doses) and 40 for those who received a first dose of BNT162b2 (approximately 12.60 per million doses). We fitted conditional Poisson models to estimate incidence rate ratios (IRRs). Vaccination with ChAdOx1 was associated with an elevated risk of incident CVST events in the 28 days following vaccination, IRR = 1.93 (95% confidence interval (CI) 1.20 to 3.11). We did not find an association between BNT162b2 and CVST in the 28 days following vaccination, IRR = 0.78 (95% CI 0.34 to 1.77). Our study had some limitations. The SCCS study design implicitly controls for variables that are constant over the observation period, but also assumes that outcome events are independent of exposure. This assumption may not be satisfied in the case of CVST, firstly because it is a serious adverse event, and secondly because the vaccination programme in the United Kingdom prioritised the clinically extremely vulnerable and those with underlying health conditions, which may have caused a selection effect for individuals more prone to CVST. Although we pooled data from several large datasets, there was still a low number of events, which may have caused imprecision in our estimates.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>In this study, we observed a small elevated risk of CVST events following vaccination with ChAdOx1, but not BNT162b2. Our analysis pooled information from large datasets from England, Scotland, and Wales. This evidence may be useful in risk\u2013benefit analyses of vaccine policies and in providing quantification of risks associated with vaccination to the general public.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pmed.1003927","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T18:25:44Z","timestamp":1645554344000},"page":"e1003927","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":53,"title":["First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3643-7859","authenticated-orcid":true,"given":"Steven","family":"Kerr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4974-3724","authenticated-orcid":true,"given":"Mark","family":"Joy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5853-4625","authenticated-orcid":true,"given":"Fatemeh","family":"Torabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5635-5957","authenticated-orcid":true,"given":"Stuart","family":"Bedston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0814-0801","authenticated-orcid":true,"given":"Ashley","family":"Akbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5181-6120","authenticated-orcid":true,"given":"Utkarsh","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7591-3256","authenticated-orcid":true,"given":"Jillian","family":"Beggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1468-1823","authenticated-orcid":true,"given":"Declan","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0646-5939","authenticated-orcid":true,"given":"Antony","family":"Chuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8277-420X","authenticated-orcid":true,"given":"Annemarie B.","family":"Docherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6551-721X","authenticated-orcid":true,"given":"David","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7976-7172","authenticated-orcid":true,"given":"Richard","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6593-9092","authenticated-orcid":true,"given":"Srinivasa Vittal","family":"Katikireddi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9362-0046","authenticated-orcid":true,"given":"Emily","family":"Lowthian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8553-2641","authenticated-orcid":true,"given":"Simon","family":"de Lusignan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5225-000X","authenticated-orcid":true,"given":"Ronan","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Marple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9466-833X","authenticated-orcid":true,"given":"Colin","family":"McCowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6772-2775","authenticated-orcid":true,"given":"Dylan","family":"McGagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"McMenamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9634-3299","authenticated-orcid":true,"given":"Emily","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1511-7944","authenticated-orcid":true,"given":"Josephine-L. K.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5977-376X","authenticated-orcid":true,"given":"Rhiannon K.","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5993-3209","authenticated-orcid":true,"given":"Jiafeng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9380-7641","authenticated-orcid":true,"given":"Lewis","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5672-0443","authenticated-orcid":true,"given":"Syed Ahmar","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4101-4535","authenticated-orcid":true,"given":"Ting","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4308-856X","authenticated-orcid":true,"given":"Sarah","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2520-526X","authenticated-orcid":true,"given":"Ruby S. M.","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6850-7578","authenticated-orcid":true,"given":"Eleftheria","family":"Vasileiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3765-8167","authenticated-orcid":true,"given":"Mark","family":"Woolhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5194-8083","authenticated-orcid":true,"given":"Colin R.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6848-5241","authenticated-orcid":true,"given":"Chris","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,2,22]]},"reference":[{"issue":"22","key":"pmed.1003927.ref001","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination","volume":"384","author":"NH Schultz","journal-title":"N Engl J Med"},{"issue":"22","key":"pmed.1003927.ref002","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination","volume":"384","author":"A Greinacher","year":"2021","journal-title":"N Engl J Med"},{"issue":"24","key":"pmed.1003927.ref003","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1001\/jama.2021.7517","article-title":"US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021","volume":"325","author":"I See","year":"2021","journal-title":"JAMA"},{"key":"pmed.1003927.ref004","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","author":"NH Schultz","journal-title":"N Engl J Med"},{"key":"pmed.1003927.ref005","article-title":"Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination","author":"M Scully","year":"2021","journal-title":"N Engl J Med"},{"key":"pmed.1003927.ref006","unstructured":"European Medicines Agency, COVID-19 vaccine safety update, 29 March 2021. [cited 2021 Sep 27]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-29-march-2021_en.pdf"},{"key":"pmed.1003927.ref007","unstructured":"European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC). Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine (ChAdOx1-S [recombinant])\u2013Vaxzevria (previously COVID-19 Vaccine AstraZeneca) (Other viral vaccines). 2021 [cited 2021 Sep 27]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/prac-recommendation\/signal-assessment-report-embolic-thrombotic-events-smq-covid-19-vaccine-chadox1-s-recombinant_en.pdf"},{"key":"pmed.1003927.ref008","article-title":"Cerebral venous sinus thrombosis (CVST) is not significantly linked to COVID-19 vaccines or non-COVID vaccines in a large multi-state US health system","author":"C Pawlowski","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"n1114","key":"pmed.1003927.ref009","article-title":"Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study","volume":"373","author":"A Potteg\u00e5rd","year":"2021","journal-title":"BMJ"},{"issue":"n1931","key":"pmed.1003927.ref010","article-title":"Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study","volume":"374","author":"J Hippisley-Cox","year":"2021","journal-title":"BMJ"},{"key":"pmed.1003927.ref011","doi-asserted-by":"crossref","first-page":"n699","DOI":"10.1136\/bmj.n699","article-title":"Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots","volume":"372","author":"J. Wise","year":"2021","journal-title":"BMJ"},{"key":"pmed.1003927.ref012","unstructured":"GOV.UK. JCVI statement on use of the AstraZeneca COVID-19 vaccine, 7 April 2021. [cited 2021 Sep 27]. Available from: https:\/\/www.gov.uk\/government\/publications\/use-of-the-astrazeneca-covid-19-vaccine-jcvi-statement\/jcvi-statement-on-use-of-the-astrazeneca-covid-19-vaccine-7-april-2021"},{"key":"pmed.1003927.ref013","unstructured":"GOV.UK. JCVI advises on COVID-19 vaccine for people aged under 40, 7 May 2021. [cited 2021 Sep 27]. Available from: https:\/\/www.gov.uk\/government\/news\/jcvi-advises-on-covid-19-vaccine-for-people-aged-under-40"},{"issue":"27","key":"pmed.1003927.ref014","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"FP Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"10269","key":"pmed.1003927.ref015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"M Voysey","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"pmed.1003927.ref016","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"LR Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"pmed.1003927.ref017","article-title":"Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England","author":"JL Bernal","year":"2021","journal-title":"medRxiv"},{"key":"pmed.1003927.ref018","article-title":"Interim findings from first dose mass COVID-19 vaccination roll-out and COVID-19 hospitalisations in Scotland: National prospective cohort study of 5.4 million people","author":"E Vasileiou","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"pmed.1003927.ref019","first-page":"E3","article-title":"Cerebral venous sinus thrombosis: review of the demographics, pathophysiology, current diagnosis, and treatment","volume":"27","author":"A Filippidis","year":"2009","journal-title":"J Neurosurg"},{"key":"pmed.1003927.ref020","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41591-021-01408-4","article-title":"First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland","volume":"27","author":"CR Simpson","year":"2021","journal-title":"Nat Med"},{"key":"pmed.1003927.ref021","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2307\/1911191","article-title":"Econometric models for count data with an application to the patents-R&D relationship.","volume":"4","author":"JA Hausman","year":"1984","journal-title":"Econometrica"},{"key":"pmed.1003927.ref022","unstructured":"Strengthening the reporting of observational studies in epidemiology (STROBE). [cited 2021 Sep 27]. Available from: https:\/\/www.strobe-statement.org"},{"key":"pmed.1003927.ref023","unstructured":"Reporting of studies using observational routinely-collected data (RECORD). [cited 2021 Sep 27]. Available from: https:\/\/www.record-statement.org"},{"key":"pmed.1003927.ref024","doi-asserted-by":"crossref","first-page":"m3731","DOI":"10.1136\/bmj.m3731","article-title":"Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study","volume":"371","author":"AK Clift","year":"2020","journal-title":"BMJ"},{"key":"pmed.1003927.ref025","doi-asserted-by":"crossref","first-page":"i4515","DOI":"10.1136\/bmj.i4515","article-title":"Self controlled case series methods: an alternative to standard epidemiological study designs","volume":"354","author":"I Petersen","year":"2016","journal-title":"BMJ"},{"issue":"3","key":"pmed.1003927.ref026","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1161\/01.STR.0000117571.76197.26","article-title":"ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT).","volume":"35","author":"JM Ferro","year":"2004","journal-title":"Stroke"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003927","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T18:26:35Z","timestamp":1645554395000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003927"}},"subtitle":[],"editor":[{"given":"Suzanne C.","family":"Cannegieter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1003927","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,22]]}}}